817636-91-2

Upstream product

• 50638-46-5 4-bromo-3-chloroanisole 
• 817636-89-8 4-(2-chloro-4-methoxyphenyl)-5-methyl-2H-pyrazol-3-ylamine 
• 441060-95-3 2-(2-chloro-4-methoxyphenyl)-3-oxo-butyronitrile 
• 170737-93-6 2-chloro-4-methoxyphenylacetonitrile 
• 817636-90-1 8-hydroxy-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine 

Downstream Products

• 817636-93-4 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine tosylate 
• 1338727-99-3 3-[2-chloro-4-(difluoromethoxy)phenyl]-N-(1-ethylpropyl)-2-methyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine 
• 857262-72-7 3-chloro-4-[8-(1-ethylpropylamino)-2-methyl-6,7-dihydro-5H-1,4,8a-triaza-s-indacen-3-yl]-phenol 
• 441060-02-2 (1-ethyl-propyl)-[3-(4-methoxy-2-chlorophenyl)-2-methyl-6,7-dihydro-5H-1,4,8a-triaza-s-indacen-8-yl]-amine 

Relevant academic research and scientific papers

6,7-Dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives as novel corticotropin-releasing factor 1 receptor antagonists

To identify an orally active corticotropin-releasing factor 1 receptor antagonist, a series of 6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives were designed, synthesized and evaluated. An in vitro study followed by in vivo and pharmacokinetic studies of these heterotricyclic compounds led us to the discovery of an orally active CRF1 receptor antagonist. The results of a structure-activity relationship study are presented.

METHANESULFONIC ACID SALT OF PYRAZOLOPYRIMIDINE COMPOUND, CRYSTAL THEREOF, AND PROCESS FOR PRODUCING THE SAME

The present invention relates to 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7 -dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine methanesulfonate, a crystal thereof, a process for the preparation thereof, and a process for the preparation o